CoChat
Sign Up
Cited by 2,724

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Proliferation, cell cycle and apoptosis in cancer

Evan, Gerard I., Vousden, Karen H.·2001·Nature
DOI 10.1038/35077213
Open this paper in CoChat — free account

Abstract

Beneath the complexity and idiopathy of every cancer lies a limited number of 'mission critical' events that have propelled the tumour cell and its progeny into uncontrolled expansion and invasion. One of these is deregulated cell proliferation, which, together with the obligate compensatory suppression of apoptosis needed to support it, provides a minimal 'platform' necessary to support further neoplastic progression. Adroit targeting of these critical events should have potent and specific therapeutic consequences.

Overview

Integrity signals

Registry

Crossref · 10.1038/35077213

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Research works printed but not linked: 75

  1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). · DOI · Paper page
  2. Oller, A. R., Rastogi, P., Morgenthaler, S. & Thilly, W. G. A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat. Res. 216, 149–161 (1989). · DOI
  3. Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317–1322 (1998). · DOI
  4. Pardee, A. B. G1 events and regulation of cell proliferation. Science 246, 603–608 (1989). · DOI · Paper page
  5. Roovers, K. & Assoian, R. K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. BioEssays 22, 818–826 (2000). · DOI
  6. Massague, J., Blain, S. W. & Lo, R. S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103, 295–309 (2000). · DOI
  7. Sangfelt, O., Erickson, S. & Grander, D. Mechanisms of interferon-induced cell cycle arrest. Front. Biosci. 5, D479–D487 (2000). · DOI
  8. Zhu, L. & Skoultchi, A. I. Coordinating cell proliferation and differentiation. Curr. Opin. Genet. Dev. 11, 91–97 (2001). · DOI
  9. Bach, S. P., Renehan, A. G. & Potten, C. S. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 21, 469–476 (2000). · DOI · Paper page
  10. Booth, C. & Potten, C. S. Gut instincts: thoughts on intestinal epithelial stem cells. J. Clin. Invest. 105, 1493–1499 (2000). · DOI
  11. Fuchs, E. & Segre, J. A. Stem cells: a new lease on life. Cell 100, 143–155 (2000). · DOI
  12. Raff, M. C. Social controls on cell survival and cell death. Nature 356, 397–400 (1992). · DOI
  13. Raff, M. et al. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262, 695–700 (1993). · DOI
  14. Hunter, T. Signaling—2000 and beyond. Cell 100, 113–127 (2000). · DOI · Paper page
  15. Baudino, T. A. & Cleveland, J. L. The Max network gone mad. Mol. Cell. Biol. 21, 691–702 (2001). · DOI
  16. Stocker, H. & Hafen, E. Genetic control of cell size. Curr. Opin. Genet. Dev. 10, 529–535 (2000). · DOI
  17. Johnston, L. A., Prober, D. A., Edgar, B. A., Eisenman, R. N. & Gallant, P. Drosophila myc regulates cellular growth during development. Cell 98, 779–790 (1999). · DOI
  18. Iritani, B. M. & Eisenman, R. N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl Acad. Sci. USA 96, 13180–13185 (1999). · DOI · Paper page
  19. Elend, M. & Eilers, M. Cell growth: downstream of Myc—to grow or to cycle? Curr. Biol. 9, R936–R938 (1999). · DOI
  20. Dang, C. V. et al. Function of the c-Myc oncogenic transcription factor. Exp. Cell Res. 253, 63–77 (1999). · DOI
  21. Pelengaris, S., Littlewood, T., Khan, M., Elia, G. & Evan, G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565–577 (1999). · DOI
  22. Pelengaris, S., Rudolph, B. & Littlewood, T. Action of Myc in vivo—proliferation and apoptosis. Curr. Opin. Genet. Dev. 10, 100–105 (2000). · DOI
  23. Gu, W. et al. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72, 309–324 (1993). · DOI
  24. Lasorella, A., Noseda, M., Beyna, M. & Iavarone, A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407, 592–598 (2000). · DOI
  25. Walczak, H. & Krammer, P. H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58–66 (2000). · DOI
  26. Vander Heiden, M. G. et al. Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival. Proc. Natl Acad. Sci. USA 97, 4666–4671 (2000). · DOI
  27. Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770–776 (2000). · DOI · Paper page
  28. Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M. & Strasser, A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287–296 (1999). · DOI
  29. Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92, 1472–1489 (2000). · DOI
  30. Stambolic, V., Mak, T. W. & Woodgett, J. R. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18, 6094–6103 (1999). · DOI
  31. Maehama, T. & Dixon, J. E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9, 125–128 (1999). · DOI
  32. Bonneau, D. & Longy, M. Mutations of the human PTEN gene. Hum. Mutat. 16, 109–122 (2000). · DOI
  33. Kandel, E. S. & Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253, 210–229 (1999). · DOI
  34. Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211 (2001). · DOI
  35. Evan, G. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 63, 119–125 (1992). · DOI
  36. Askew, D., Ashmun, R., Simmons, B. & Cleveland, J. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis. Oncogene 6, 1915–1922 (1991).
  37. Harrington, E. A., Fanidi, A. & Evan, G. I. Oncogenes and cell death. Curr. Opin. Genet. Dev. 4, 120–129 (1994). · DOI
  38. Evan, G. & Littlewood, T. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3, 44–49 (1993). · DOI
  39. Almasan, A. et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl Acad. Sci. USA 92, 5436–5440 (1995). · DOI
  40. Qin, X. Q., Livingston, D. M., Kaelin, W. G. Jr & Adams, P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl Acad. Sci. USA 91, 10918–10922 (1994). · DOI
  41. Shan, B. & Lee, W. H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14, 8166–8173 (1994).
  42. Wu, X. & Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl Acad. Sci. USA 91, 3602–3606 (1994). · DOI
  43. Dimri, G. P., Itahana, K., Acosta, M. & Campisi, J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol. Cell. Biol. 20, 273–285 (2000). · DOI
  44. Hirakawa, T. & Ruley, H. E. Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene. Proc. Natl Acad. Sci. USA 85, 1519–1523 (1988). · DOI
  45. Ferbeyre, G. et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015–2027 (2000). · DOI · Paper page
  46. Fanidi, A., Harrington, E. & Evan, G. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554–556 (1992). · DOI
  47. Bissonnette, R., Echeverri, F., Mahboubi, A. & Green, D. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552–554 (1992). · DOI
  48. Wagner, A. J., Small, M. B. & Hay, N. Myc-mediated apoptosis is blocked by ectopic expression of bcl-2. Mol. Cell. Biol. 13, 2432–2440 (1993).
  49. Harrington, E. A., Bennett, M. R., Fanidi, A. & Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13, 3286–3295 (1994). · DOI
  50. Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331–333 (1990). · DOI
  51. Phillips, A. C., Ernst, M. K., Bates, S., Rice, N. R. & Vousden, K. H. E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways. Mol. Cell. 4, 771–781 (1999). · DOI
  52. Hueber, A.-O. et al. Requirement for the CD95 receptor-ligand pathway in c-Myc induced apoptosis. Science 278, 1305–1309 (1997). · DOI
  53. Klefstrom, J. et al. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α. EMBO J. 13, 5442–5450 (1994). · DOI
  54. Lutz, W., Fulda, S., Jeremias, I., Debatin, K. M. & Schwab, M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 17, 339–346 (1998). · DOI
  55. Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94–99 (2000). · DOI · Paper page
  56. Woods, D. B. & Vousden, K. H. Regulation of p53 function. Exp. Cell Res. 264, 56–66 (2001). · DOI
  57. Frame, S. et al. Epithelial carcinogenesis in the mouse: correlating the genetics and the biology. Phil. Trans. R. Soc. Lond. B 353, 839–845 (1998). · DOI
  58. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990). · DOI · Paper page
  59. Esteller, M. et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60, 129–133 (2000).
  60. Kemp, C. J., Donehower, L. A., Bradley, A. & Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813–822 (1993). · DOI
  61. Greenhalgh, D. A., Wang, X. J., Donehower, L. A. & Roop, D. R. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 56, 4413–4423 (1996).
  62. Wang, X. J., Greenhalgh, D. A., Donehower, L. A. & Roop, D. R. Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol. Carcinogenesis 29, 67–75 (2000). · DOI
  63. Schmitt, C. A. & Lowe, S. W. Apoptosis and therapy. J. Pathol. 187, 127–137 (1999). · DOI
  64. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science 287, 1969–1973 (2000). · DOI
  65. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by myc in hematopoietic lineages. Mol. Cell 4, 199–207 (1999). · DOI
  66. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999). · DOI
  67. Brandvold, K. A., Neiman, P. & Ruddell, A. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 19, 2780–2785 (2000). · DOI
  68. Breit, S. et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res. 60, 4596–4601 (2000).
  69. Ngo, C. V. et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ. 11, 201–210 (2000).
  70. Janz, A., Sevignani, C., Kenyon, K., Ngo, C. V. & Thomas-Tikhonenko, A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res. 28, 2268–2275 (2000). · DOI
  71. O'Dwyer, M. E. & Druker, B. J. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukamia. Curr. Opin. Oncol. 12, 594–597 (2000). · DOI
  72. Morin, M. J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19, 6574–6583 (2000). · DOI
  73. Krek, W. VHL takes HIF's breath away. Nature Cell Biol. 2, E1–E3 (2000). · DOI
  74. Huang, Y. Q., Li, J. J. & Karpatkin, S. Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J. Biol. Chem. 275, 6462–6468 (2000). · DOI
  75. Chen, Y. N. et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl Acad. Sci. USA 96, 4325–4329 (1999). · DOI

Cited by

See all 2,724

Metadata

Authors
Evan, G. I., & Vousden, K. H.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2001-05-01
Volume
411
Issue
6835
Pages
342-348
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/35077213
Cited by
2,724
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proliferation, cell cycle and apoptosis in cancer. https://app.cochat.ai/papers/10.1038/35077213
The paper
Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature. https://doi.org/10.1038/35077213